Financing ·
PDS Biotech reports median overall survival of 39.3 months in Phase 2 trial, closes up to $22.3M PIPE
PDSBPDS Biotechnology Corp
PDS Biotechnology Corporation announced the publication of Phase 2 VERSATILE-002 trial results for its HPV16-targeted immunotherapy PDS0101 in combination with pembrolizumab in JAMA Oncology. The data showed a median overall survival of 39.3 months and an objective response rate of 36% in patients with CPS ≥ 1, outperforming standard-of-care benchmarks. Concurrently, the company reported the initial closing of up to $22.3 million in PIPE financing led by Nant Capital, alongside an exclusive negotiation agreement for PDS0101 licensing rights. PDS Biotechnology is a clinical-stage biotechnology company developing targeted immunotherapies and cancer vaccines.